Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does SITAGLIPTIN Cause Pancreatic carcinoma? 1,142 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 1,142 reports of Pancreatic carcinoma have been filed in association with SITAGLIPTIN (JANUVIA). This represents 5.7% of all adverse event reports for SITAGLIPTIN.

1,142
Reports of Pancreatic carcinoma with SITAGLIPTIN
5.7%
of all SITAGLIPTIN reports
725
Deaths
361
Hospitalizations

How Dangerous Is Pancreatic carcinoma From SITAGLIPTIN?

Of the 1,142 reports, 725 (63.5%) resulted in death, 361 (31.6%) required hospitalization, and 141 (12.3%) were considered life-threatening.

Is Pancreatic carcinoma Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for SITAGLIPTIN. However, 1,142 reports have been filed with the FAERS database.

What Other Side Effects Does SITAGLIPTIN Cause?

Blood glucose increased (1,427) Product dose omission issue (1,125) Drug ineffective (1,057) No adverse event (994) Nausea (936) Pancreatitis (922) Diabetes mellitus inadequate control (744) Diarrhoea (712) Hypoglycaemia (674) Death (654)

What Other Drugs Cause Pancreatic carcinoma?

RANITIDINE (15,752) PANCRELIPASE AMYLASE\PANCRELIPASE LIPASE\PANCRELIPASE PROTEASE (838) EXENATIDE (781) LIRAGLUTIDE (680) METFORMIN\SITAGLIPTIN (431) PACLITAXEL (325) SEMAGLUTIDE (237) DULAGLUTIDE (229) ADALIMUMAB (213) JANUVIA (185)

Which SITAGLIPTIN Alternatives Have Lower Pancreatic carcinoma Risk?

SITAGLIPTIN vs SOAP SITAGLIPTIN vs SODIUM SITAGLIPTIN vs SODIUM BICARBONATE SITAGLIPTIN vs SODIUM BICARBONATE\SODIUM SITAGLIPTIN vs SODIUM BORATE

Related Pages

SITAGLIPTIN Full Profile All Pancreatic carcinoma Reports All Drugs Causing Pancreatic carcinoma SITAGLIPTIN Demographics